Ascendis Pharma A/S (BVMF:A1SN34)

Ascendis Pharma Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	720.13	363.64	266.72	51.17	7.78
Revenue Growth (YoY)	98.03%	36.34%	421.20%	557.93%	11.87%
Cost of Revenue	94.92	44.26	-44.4	12.14	3.52
Gross Profit	625.22	319.38	222.32	39.04	4.26
Selling, General & Admin	457.87	291.14	-264.41	221.23	160.18
Research & Development	303.62	307	-413.45	379.62	295.87
Operating Income	-136.27	-278.76	-455.54	-561.81	-451.79
Interest Income	114	25.61	43.86	52.18	59.72
Interest Expense	-206.69	-100.03	44.07	-50.49	-3.91
Other Non-Operating Income (Expense)	16.31	-20.06	-18.4	-17.7	12.04
Total Non-Operating Income (Expense)	-76.38	-94.48	69.53	-16	67.85
Pretax Income	-212.65	-373.24	-474.14	-577.82	-383.94
Provision for Income Taxes	15.38	4.84	7.3	5.38	-0.37
Net Income	-228.03	-378.08	-481.45	-583.19	-383.58
Net Income to Common	-228.03	-378.08	-481.45	-583.19	-383.58
Shares Outstanding (Basic)	61	58	56	56	55
Shares Outstanding (Diluted)	61	58	56	56	55
Shares Change (YoY)	4.69%	2.85%	0.38%	2.37%	8.21%
EPS (Basic)	-3.76	-6.53	-8.55	-10.40	-7.00
EPS (Diluted)	-3.76	-6.53	-8.55	-10.40	-7.00
Shares Outstanding	61.38	59.84	56.56	55.94	54.77
Free Cash Flow	45.41	-307.62	-469.8	-510.19	-441.35
Free Cash Flow Per Share	0.75	-5.31	-8.35	-9.10	-8.06
Gross Margin	86.82%	87.83%	83.36%	76.28%	54.71%
Operating Margin	-18.92%	-76.66%	-170.80%	-1097.85%	-5808.59%
Profit Margin	-31.67%	-103.97%	-180.51%	-1139.63%	-4931.56%
FCF Margin	6.31%	-84.60%	-176.14%	-996.97%	-5674.38%
EBITDA	-118.58	-261.05	-436.63	-543.86	-436.4
EBITDA Margin	-16.47%	-71.79%	-163.70%	-1062.76%	-5610.71%
EBIT	-136.27	-278.76	-455.54	-561.81	-451.79
EBIT Margin	-18.92%	-76.66%	-170.80%	-1097.85%	-5808.59%
Effective Tax Rate	-7.23%	-1.30%	-1.54%	-0.93%	0.10%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.